| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonectomy | 58 | 2023 | 862 | 7.240 |
Why?
|
| Lung Neoplasms | 127 | 2024 | 12012 | 4.770 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 71 | 2024 | 5566 | 3.270 |
Why?
|
| Esophagectomy | 32 | 2024 | 947 | 2.480 |
Why?
|
| Esophageal Neoplasms | 47 | 2024 | 3240 | 2.380 |
Why?
|
| Thoracic Surgery, Video-Assisted | 14 | 2022 | 211 | 2.180 |
Why?
|
| Pleural Neoplasms | 17 | 2021 | 487 | 2.100 |
Why?
|
| Thoracic Surgical Procedures | 12 | 2022 | 261 | 1.890 |
Why?
|
| Pain, Postoperative | 8 | 2021 | 657 | 1.700 |
Why?
|
| Mesothelioma | 15 | 2022 | 560 | 1.690 |
Why?
|
| Metastasectomy | 10 | 2023 | 209 | 1.400 |
Why?
|
| Colorectal Neoplasms | 18 | 2023 | 3704 | 1.290 |
Why?
|
| Postoperative Complications | 31 | 2024 | 5690 | 1.260 |
Why?
|
| Lung Diseases | 6 | 2021 | 755 | 1.210 |
Why?
|
| Bupivacaine | 3 | 2020 | 74 | 1.210 |
Why?
|
| Pain Management | 5 | 2021 | 715 | 1.200 |
Why?
|
| Adenocarcinoma | 32 | 2023 | 7975 | 1.140 |
Why?
|
| Thoracic Surgery | 4 | 2021 | 280 | 1.110 |
Why?
|
| Analgesia, Epidural | 3 | 2017 | 101 | 1.100 |
Why?
|
| Radiosurgery | 13 | 2021 | 1368 | 1.090 |
Why?
|
| Retrospective Studies | 111 | 2024 | 39780 | 1.080 |
Why?
|
| Neoplasm Recurrence, Local | 35 | 2022 | 10365 | 1.070 |
Why?
|
| Trachea | 2 | 2018 | 290 | 1.070 |
Why?
|
| Neoplasm Staging | 66 | 2023 | 13993 | 1.070 |
Why?
|
| Aged | 158 | 2024 | 73471 | 1.010 |
Why?
|
| Middle Aged | 171 | 2024 | 90395 | 0.990 |
Why?
|
| Nerve Block | 3 | 2020 | 185 | 0.960 |
Why?
|
| Humans | 278 | 2024 | 271884 | 0.930 |
Why?
|
| Male | 187 | 2024 | 128957 | 0.840 |
Why?
|
| Thoracotomy | 9 | 2022 | 218 | 0.830 |
Why?
|
| Female | 188 | 2024 | 149143 | 0.820 |
Why?
|
| Treatment Outcome | 91 | 2024 | 33863 | 0.770 |
Why?
|
| Intercostal Nerves | 3 | 2020 | 31 | 0.760 |
Why?
|
| Analgesics, Opioid | 7 | 2021 | 1458 | 0.750 |
Why?
|
| Propensity Score | 14 | 2021 | 776 | 0.740 |
Why?
|
| Radiotherapy, Intensity-Modulated | 9 | 2020 | 2168 | 0.730 |
Why?
|
| Lung | 15 | 2023 | 3294 | 0.710 |
Why?
|
| Neoadjuvant Therapy | 25 | 2024 | 5211 | 0.700 |
Why?
|
| Anesthetics, Local | 4 | 2020 | 175 | 0.690 |
Why?
|
| Coronary Disease | 22 | 2001 | 783 | 0.690 |
Why?
|
| Perioperative Care | 4 | 2019 | 447 | 0.650 |
Why?
|
| Aged, 80 and over | 66 | 2021 | 31042 | 0.630 |
Why?
|
| Diaphragm | 2 | 2017 | 187 | 0.620 |
Why?
|
| Bronchi | 5 | 2018 | 330 | 0.620 |
Why?
|
| Treatment Refusal | 1 | 2019 | 127 | 0.620 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 916 | 0.610 |
Why?
|
| Patient Discharge | 5 | 2022 | 711 | 0.610 |
Why?
|
| Adult | 92 | 2024 | 81857 | 0.600 |
Why?
|
| Hydrothorax | 1 | 2017 | 18 | 0.580 |
Why?
|
| Risk Assessment | 21 | 2020 | 6883 | 0.580 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2017 | 53 | 0.570 |
Why?
|
| Shoulder Joint | 1 | 2017 | 63 | 0.560 |
Why?
|
| Time Factors | 31 | 2023 | 13130 | 0.550 |
Why?
|
| Margins of Excision | 1 | 2018 | 314 | 0.550 |
Why?
|
| Thoracentesis | 1 | 2017 | 61 | 0.550 |
Why?
|
| Polytetrafluoroethylene | 1 | 2017 | 109 | 0.550 |
Why?
|
| Video-Assisted Surgery | 1 | 2016 | 29 | 0.550 |
Why?
|
| Chest Tubes | 4 | 2024 | 118 | 0.540 |
Why?
|
| Stents | 20 | 2001 | 1015 | 0.540 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 481 | 0.540 |
Why?
|
| Follow-Up Studies | 49 | 2021 | 15267 | 0.530 |
Why?
|
| Preoperative Care | 9 | 2019 | 1552 | 0.530 |
Why?
|
| Hepatectomy | 8 | 2020 | 1013 | 0.520 |
Why?
|
| Angioplasty, Balloon, Coronary | 14 | 2001 | 229 | 0.520 |
Why?
|
| Acellular Dermis | 1 | 2017 | 101 | 0.520 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2020 | 640 | 0.510 |
Why?
|
| Liver Neoplasms | 11 | 2021 | 4809 | 0.500 |
Why?
|
| Lymph Nodes | 11 | 2021 | 3080 | 0.500 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 690 | 0.490 |
Why?
|
| Chemoradiotherapy, Adjuvant | 7 | 2021 | 562 | 0.480 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 508 | 0.480 |
Why?
|
| Anastomotic Leak | 3 | 2024 | 83 | 0.480 |
Why?
|
| Sarcoma | 7 | 2020 | 1842 | 0.470 |
Why?
|
| Survival Rate | 42 | 2024 | 12533 | 0.470 |
Why?
|
| Disease-Free Survival | 30 | 2021 | 10259 | 0.470 |
Why?
|
| Chemoradiotherapy | 9 | 2021 | 2029 | 0.470 |
Why?
|
| Databases, Factual | 13 | 2023 | 2287 | 0.470 |
Why?
|
| Risk Factors | 31 | 2023 | 18045 | 0.460 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 223 | 0.450 |
Why?
|
| Empyema, Pleural | 3 | 2004 | 48 | 0.430 |
Why?
|
| Radiotherapy, Conformal | 3 | 2020 | 898 | 0.410 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2020 | 7790 | 0.400 |
Why?
|
| Prognosis | 37 | 2023 | 22537 | 0.400 |
Why?
|
| Thoracic Duct | 1 | 2011 | 13 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 13 | 2021 | 5603 | 0.380 |
Why?
|
| Endothelial Cells | 2 | 2014 | 1047 | 0.380 |
Why?
|
| Pleura | 5 | 2021 | 130 | 0.370 |
Why?
|
| Thymus Neoplasms | 3 | 2020 | 418 | 0.360 |
Why?
|
| Length of Stay | 8 | 2024 | 2015 | 0.360 |
Why?
|
| Cardiology | 1 | 2016 | 574 | 0.360 |
Why?
|
| Postoperative Care | 5 | 2021 | 731 | 0.350 |
Why?
|
| Thoracic Wall | 3 | 2018 | 188 | 0.330 |
Why?
|
| Esophagogastric Junction | 5 | 2023 | 556 | 0.330 |
Why?
|
| Survival Analysis | 23 | 2019 | 9325 | 0.320 |
Why?
|
| Blood Vessel Prosthesis | 4 | 1992 | 372 | 0.320 |
Why?
|
| Combined Modality Therapy | 20 | 2023 | 9044 | 0.320 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2024 | 6270 | 0.320 |
Why?
|
| Proton Therapy | 6 | 2020 | 1638 | 0.310 |
Why?
|
| Reoperation | 8 | 2019 | 1389 | 0.310 |
Why?
|
| Thoracic Neoplasms | 3 | 2018 | 349 | 0.310 |
Why?
|
| Proportional Hazards Models | 15 | 2024 | 5118 | 0.300 |
Why?
|
| Graft Occlusion, Vascular | 7 | 2001 | 114 | 0.300 |
Why?
|
| Pain Measurement | 6 | 2020 | 1016 | 0.290 |
Why?
|
| Texas | 15 | 2021 | 6435 | 0.290 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 5928 | 0.280 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2019 | 113 | 0.280 |
Why?
|
| Pneumonia, Aspiration | 1 | 2006 | 45 | 0.280 |
Why?
|
| Auranofin | 2 | 2016 | 36 | 0.270 |
Why?
|
| Multivariate Analysis | 19 | 2023 | 4352 | 0.270 |
Why?
|
| Young Adult | 21 | 2020 | 22108 | 0.270 |
Why?
|
| Thymoma | 2 | 2017 | 252 | 0.270 |
Why?
|
| Streptococcal Infections | 2 | 2010 | 312 | 0.270 |
Why?
|
| Opioid-Related Disorders | 3 | 2019 | 415 | 0.260 |
Why?
|
| Heparin | 2 | 2019 | 346 | 0.260 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 10750 | 0.260 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2017 | 166 | 0.260 |
Why?
|
| Adolescent | 17 | 2023 | 32663 | 0.260 |
Why?
|
| Anastomosis, Surgical | 6 | 2018 | 371 | 0.250 |
Why?
|
| Coronary Angiography | 20 | 2001 | 568 | 0.250 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2021 | 1259 | 0.250 |
Why?
|
| Creatine Kinase | 7 | 2001 | 97 | 0.250 |
Why?
|
| Dasatinib | 2 | 2020 | 881 | 0.250 |
Why?
|
| Chylothorax | 2 | 2024 | 43 | 0.250 |
Why?
|
| Treatment Failure | 6 | 2019 | 1432 | 0.250 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 2668 | 0.250 |
Why?
|
| Dental Care | 1 | 2004 | 15 | 0.250 |
Why?
|
| Viridans Streptococci | 1 | 2004 | 17 | 0.240 |
Why?
|
| Ipilimumab | 4 | 2023 | 759 | 0.240 |
Why?
|
| Robotic Surgical Procedures | 3 | 2021 | 527 | 0.240 |
Why?
|
| Thymectomy | 2 | 2020 | 80 | 0.240 |
Why?
|
| Radiography, Thoracic | 2 | 2017 | 474 | 0.240 |
Why?
|
| Esophagoscopy | 4 | 2021 | 310 | 0.240 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2016 | 398 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2023 | 3978 | 0.230 |
Why?
|
| Quality of Life | 3 | 2023 | 4749 | 0.230 |
Why?
|
| Logistic Models | 13 | 2019 | 3469 | 0.230 |
Why?
|
| Cohort Studies | 17 | 2019 | 9491 | 0.230 |
Why?
|
| Salvage Therapy | 6 | 2021 | 2119 | 0.230 |
Why?
|
| Liposomes | 2 | 2017 | 710 | 0.230 |
Why?
|
| Prospective Studies | 19 | 2024 | 13400 | 0.230 |
Why?
|
| Patient Selection | 8 | 2021 | 2043 | 0.230 |
Why?
|
| Peritoneal Neoplasms | 2 | 2023 | 856 | 0.220 |
Why?
|
| Saphenous Vein | 5 | 2001 | 59 | 0.220 |
Why?
|
| Ultrasonography, Interventional | 9 | 2010 | 418 | 0.220 |
Why?
|
| Octreotide | 1 | 2024 | 132 | 0.220 |
Why?
|
| Gastrointestinal Agents | 1 | 2024 | 118 | 0.220 |
Why?
|
| Chi-Square Distribution | 7 | 2017 | 1327 | 0.220 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2013 | 64 | 0.220 |
Why?
|
| Surgical Flaps | 4 | 2012 | 882 | 0.210 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 784 | 0.210 |
Why?
|
| Quality Improvement | 2 | 2020 | 918 | 0.210 |
Why?
|
| Thyroid Diseases | 1 | 2022 | 88 | 0.200 |
Why?
|
| Anticoagulants | 2 | 2019 | 792 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 544 | 0.200 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 101 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2020 | 2270 | 0.200 |
Why?
|
| ErbB Receptors | 5 | 2020 | 2383 | 0.200 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2017 | 352 | 0.190 |
Why?
|
| Lymphatic Metastasis | 9 | 2021 | 4968 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 2429 | 0.190 |
Why?
|
| Ticlopidine | 2 | 2017 | 54 | 0.190 |
Why?
|
| Mediastinum | 5 | 2019 | 278 | 0.190 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 25 | 0.190 |
Why?
|
| Mutation | 9 | 2020 | 15924 | 0.190 |
Why?
|
| Radiation Injuries | 4 | 2017 | 1472 | 0.190 |
Why?
|
| Cough | 2 | 2016 | 126 | 0.190 |
Why?
|
| Fluid Therapy | 1 | 2022 | 195 | 0.180 |
Why?
|
| Goals | 1 | 2022 | 190 | 0.180 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 508 | 0.180 |
Why?
|
| SEER Program | 3 | 2019 | 1047 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 7 | 2019 | 4071 | 0.180 |
Why?
|
| Melanoma | 3 | 2023 | 5592 | 0.180 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 653 | 0.180 |
Why?
|
| Mediastinal Diseases | 2 | 2006 | 59 | 0.180 |
Why?
|
| Dexmedetomidine | 1 | 2021 | 89 | 0.180 |
Why?
|
| Bronchoscopy | 3 | 2018 | 481 | 0.180 |
Why?
|
| Vascular Malformations | 1 | 2021 | 88 | 0.180 |
Why?
|
| Mediastinoscopy | 2 | 2018 | 33 | 0.180 |
Why?
|
| Barrett Esophagus | 2 | 2021 | 561 | 0.180 |
Why?
|
| Patient Readmission | 3 | 2021 | 592 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 718 | 0.180 |
Why?
|
| Tumor Burden | 4 | 2020 | 2035 | 0.180 |
Why?
|
| Telephone | 2 | 2021 | 160 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 97 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1388 | 0.170 |
Why?
|
| Hepatic Veins | 1 | 2000 | 59 | 0.170 |
Why?
|
| Cholelithiasis | 1 | 1999 | 49 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 138 | 0.170 |
Why?
|
| Common Bile Duct | 1 | 2019 | 28 | 0.170 |
Why?
|
| Suture Techniques | 2 | 2007 | 292 | 0.170 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 1741 | 0.170 |
Why?
|
| Perioperative Period | 3 | 2016 | 150 | 0.160 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 180 | 0.160 |
Why?
|
| Incidence | 10 | 2021 | 5861 | 0.160 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1999 | 76 | 0.160 |
Why?
|
| Microwaves | 1 | 2018 | 33 | 0.160 |
Why?
|
| Dietary Carbohydrates | 1 | 2019 | 128 | 0.160 |
Why?
|
| Stomach Neoplasms | 2 | 2023 | 2321 | 0.160 |
Why?
|
| Heterografts | 3 | 2019 | 745 | 0.160 |
Why?
|
| Bacteremia | 1 | 2004 | 722 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 417 | 0.160 |
Why?
|
| Positron-Emission Tomography | 6 | 2021 | 2198 | 0.160 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 4891 | 0.150 |
Why?
|
| Sepsis | 3 | 2000 | 689 | 0.150 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 134 | 0.150 |
Why?
|
| Costs and Cost Analysis | 2 | 2010 | 311 | 0.150 |
Why?
|
| Coronary Vessels | 6 | 2005 | 643 | 0.150 |
Why?
|
| Genes, ras | 2 | 2018 | 681 | 0.150 |
Why?
|
| Predictive Value of Tests | 8 | 2020 | 4998 | 0.150 |
Why?
|
| Surgical Oncology | 1 | 2020 | 208 | 0.150 |
Why?
|
| Preoperative Period | 2 | 2014 | 349 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 1904 | 0.150 |
Why?
|
| Glottis | 1 | 2018 | 68 | 0.150 |
Why?
|
| Carcinoid Tumor | 1 | 2020 | 282 | 0.150 |
Why?
|
| Natural Language Processing | 1 | 2018 | 119 | 0.150 |
Why?
|
| Cardiovascular Diseases | 4 | 2015 | 2307 | 0.150 |
Why?
|
| Hemorrhage | 2 | 2019 | 747 | 0.150 |
Why?
|
| Ketamine | 1 | 2021 | 243 | 0.150 |
Why?
|
| Ultrasonography | 4 | 2019 | 1943 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2020 | 612 | 0.150 |
Why?
|
| Flow Cytometry | 4 | 2016 | 3078 | 0.150 |
Why?
|
| Radiopharmaceuticals | 3 | 2021 | 1338 | 0.150 |
Why?
|
| Bronchial Diseases | 3 | 2006 | 47 | 0.140 |
Why?
|
| Epithelium | 1 | 2019 | 805 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2020 | 2317 | 0.140 |
Why?
|
| Stomach | 2 | 2012 | 405 | 0.140 |
Why?
|
| Intraoperative Complications | 1 | 2019 | 288 | 0.140 |
Why?
|
| Teratoma | 1 | 2019 | 253 | 0.140 |
Why?
|
| Vaccines, Subunit | 1 | 2017 | 127 | 0.140 |
Why?
|
| Calcium | 1 | 2013 | 1594 | 0.140 |
Why?
|
| Hyperemia | 2 | 2014 | 37 | 0.140 |
Why?
|
| Thoracoplasty | 1 | 2016 | 17 | 0.140 |
Why?
|
| Angioplasty, Laser | 3 | 2001 | 5 | 0.140 |
Why?
|
| Esophagus | 2 | 2012 | 564 | 0.140 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 41 | 0.130 |
Why?
|
| Atherectomy, Coronary | 4 | 2000 | 19 | 0.130 |
Why?
|
| Airway Obstruction | 1 | 1999 | 272 | 0.130 |
Why?
|
| Antithrombins | 1 | 2016 | 62 | 0.130 |
Why?
|
| Endosonography | 5 | 2017 | 549 | 0.130 |
Why?
|
| Social Media | 1 | 2020 | 211 | 0.130 |
Why?
|
| Sex Factors | 7 | 2020 | 2206 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1014 | 0.130 |
Why?
|
| Pulmonary Medicine | 1 | 2016 | 42 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 606 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 16610 | 0.130 |
Why?
|
| Hospital Mortality | 5 | 2018 | 1317 | 0.130 |
Why?
|
| Lymphopenia | 1 | 2017 | 211 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2019 | 1132 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 153 | 0.130 |
Why?
|
| Tracheostomy | 1 | 2018 | 247 | 0.130 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 995 | 0.130 |
Why?
|
| Myocardial Revascularization | 3 | 2000 | 135 | 0.120 |
Why?
|
| Aftercare | 3 | 2022 | 255 | 0.120 |
Why?
|
| Smoking Cessation | 1 | 2021 | 768 | 0.120 |
Why?
|
| Anesthesia, General | 1 | 2016 | 221 | 0.120 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 34 | 0.120 |
Why?
|
| Smoking | 3 | 2021 | 2538 | 0.120 |
Why?
|
| Hospital Charges | 1 | 2015 | 89 | 0.120 |
Why?
|
| Surgical Mesh | 1 | 2016 | 211 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2016 | 422 | 0.120 |
Why?
|
| Injections | 1 | 2015 | 286 | 0.120 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 272 | 0.120 |
Why?
|
| Isoenzymes | 6 | 2001 | 663 | 0.120 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2014 | 30 | 0.120 |
Why?
|
| Intubation | 1 | 1994 | 42 | 0.120 |
Why?
|
| Radiation Dosage | 1 | 2019 | 1043 | 0.120 |
Why?
|
| Patient Safety | 2 | 2017 | 655 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 699 | 0.120 |
Why?
|
| Photons | 1 | 2017 | 537 | 0.120 |
Why?
|
| United States | 10 | 2023 | 16050 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 550 | 0.120 |
Why?
|
| Case-Control Studies | 6 | 2016 | 6236 | 0.120 |
Why?
|
| Thoracoscopes | 1 | 1993 | 5 | 0.110 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2014 | 39 | 0.110 |
Why?
|
| Organ Sparing Treatments | 1 | 2015 | 280 | 0.110 |
Why?
|
| Radiation Pneumonitis | 2 | 2014 | 313 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 692 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 267 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2014 | 154 | 0.110 |
Why?
|
| Lymphocytes | 2 | 2016 | 1280 | 0.110 |
Why?
|
| Pleural Diseases | 1 | 1993 | 58 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2013 | 87 | 0.110 |
Why?
|
| Anesthesia, Local | 1 | 2013 | 61 | 0.110 |
Why?
|
| Prostheses and Implants | 2 | 1996 | 296 | 0.110 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2013 | 63 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 2472 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2018 | 12222 | 0.110 |
Why?
|
| Subclavian Vein | 2 | 2011 | 44 | 0.110 |
Why?
|
| Fentanyl | 1 | 2014 | 153 | 0.110 |
Why?
|
| Aortic Valve | 1 | 2016 | 484 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2014 | 271 | 0.110 |
Why?
|
| Myocardial Infarction | 9 | 2016 | 1304 | 0.110 |
Why?
|
| Esophagoplasty | 1 | 2012 | 28 | 0.100 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2013 | 124 | 0.100 |
Why?
|
| Microtubules | 1 | 2014 | 330 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 633 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 460 | 0.100 |
Why?
|
| Precancerous Conditions | 2 | 2009 | 1065 | 0.100 |
Why?
|
| Registries | 6 | 2018 | 2250 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 709 | 0.100 |
Why?
|
| Comorbidity | 1 | 2019 | 2439 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 4 | 2021 | 879 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 1575 | 0.100 |
Why?
|
| Fingers | 1 | 2012 | 129 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2021 | 2335 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1972 | 0.100 |
Why?
|
| Immunohistochemistry | 6 | 2015 | 7822 | 0.100 |
Why?
|
| Genome, Human | 2 | 2020 | 1885 | 0.100 |
Why?
|
| Cardiac Catheterization | 1 | 2016 | 693 | 0.100 |
Why?
|
| Omentum | 1 | 2012 | 107 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1884 | 0.100 |
Why?
|
| Coronary Artery Bypass | 3 | 2000 | 568 | 0.100 |
Why?
|
| Age Factors | 8 | 2020 | 5520 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2012 | 239 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 522 | 0.100 |
Why?
|
| Precision Medicine | 2 | 2020 | 1207 | 0.100 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 532 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 1163 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 443 | 0.100 |
Why?
|
| Lymphatic System | 1 | 2011 | 56 | 0.100 |
Why?
|
| Aortic Valve Stenosis | 1 | 2016 | 401 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 2352 | 0.100 |
Why?
|
| Jejunum | 1 | 2012 | 234 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2023 | 1409 | 0.090 |
Why?
|
| Exercise Therapy | 1 | 2014 | 292 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1841 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 4137 | 0.090 |
Why?
|
| Microvessels | 1 | 2012 | 141 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 487 | 0.090 |
Why?
|
| Staphylococcal Infections | 3 | 1992 | 682 | 0.090 |
Why?
|
| Dumping Syndrome | 1 | 2010 | 7 | 0.090 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 5195 | 0.090 |
Why?
|
| Gene Dosage | 1 | 2014 | 829 | 0.090 |
Why?
|
| Angioplasty, Balloon | 3 | 2001 | 176 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2016 | 1327 | 0.090 |
Why?
|
| Bronchogenic Cyst | 1 | 2010 | 21 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 1566 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2016 | 1497 | 0.090 |
Why?
|
| Drainage | 2 | 2021 | 448 | 0.090 |
Why?
|
| Anesthesia | 1 | 2014 | 306 | 0.090 |
Why?
|
| Ulcer | 1 | 2011 | 80 | 0.090 |
Why?
|
| Analysis of Variance | 5 | 2018 | 2337 | 0.090 |
Why?
|
| Esophageal Diseases | 1 | 2011 | 79 | 0.090 |
Why?
|
| Neutrophils | 1 | 2015 | 876 | 0.090 |
Why?
|
| Radiotherapy Dosage | 4 | 2016 | 4003 | 0.090 |
Why?
|
| Respiratory Sounds | 1 | 2010 | 93 | 0.090 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2009 | 37 | 0.090 |
Why?
|
| Lymphatic Vessels | 1 | 2011 | 140 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2023 | 505 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2010 | 698 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 536 | 0.080 |
Why?
|
| Prosthesis-Related Infections | 1 | 1992 | 229 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 355 | 0.080 |
Why?
|
| Veins | 2 | 2000 | 166 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1720 | 0.080 |
Why?
|
| Child | 6 | 2018 | 30492 | 0.080 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 908 | 0.080 |
Why?
|
| Genomics | 4 | 2024 | 2830 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2020 | 1437 | 0.080 |
Why?
|
| Thoracoscopy | 2 | 2019 | 103 | 0.080 |
Why?
|
| Estrogen Receptor beta | 1 | 2009 | 167 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 2174 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2085 | 0.080 |
Why?
|
| Overweight | 1 | 2011 | 489 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2008 | 142 | 0.080 |
Why?
|
| Gastrectomy | 2 | 2023 | 476 | 0.080 |
Why?
|
| Vascular Neoplasms | 1 | 2009 | 113 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 14875 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 3947 | 0.070 |
Why?
|
| Adenomatous Polyps | 1 | 2007 | 45 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2016 | 1463 | 0.070 |
Why?
|
| Recurrence | 8 | 2023 | 4886 | 0.070 |
Why?
|
| Mucous Membrane | 1 | 2008 | 264 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2016 | 1296 | 0.070 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 365 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 1060 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 1599 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 325 | 0.070 |
Why?
|
| Swine | 4 | 1992 | 1610 | 0.070 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2006 | 3 | 0.070 |
Why?
|
| Mice, Nude | 1 | 2014 | 4359 | 0.070 |
Why?
|
| Pneumothorax | 2 | 2001 | 166 | 0.070 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2008 | 261 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 3539 | 0.070 |
Why?
|
| Lymph Node Excision | 3 | 2021 | 2054 | 0.070 |
Why?
|
| Coronary Artery Disease | 3 | 2000 | 946 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2011 | 2258 | 0.070 |
Why?
|
| Conjunctival Diseases | 1 | 2006 | 36 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7471 | 0.070 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 5330 | 0.070 |
Why?
|
| Incidental Findings | 1 | 2007 | 282 | 0.070 |
Why?
|
| Animals | 11 | 2019 | 62807 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2021 | 2349 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 2 | 2009 | 111 | 0.060 |
Why?
|
| Inhalation Exposure | 1 | 2005 | 46 | 0.060 |
Why?
|
| Vehicle Emissions | 1 | 2005 | 25 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2005 | 103 | 0.060 |
Why?
|
| Warfare | 2 | 1995 | 46 | 0.060 |
Why?
|
| Species Specificity | 3 | 1991 | 810 | 0.060 |
Why?
|
| Exercise | 1 | 2013 | 1214 | 0.060 |
Why?
|
| Myeloid Cells | 1 | 2006 | 277 | 0.060 |
Why?
|
| Colonic Polyps | 1 | 2007 | 221 | 0.060 |
Why?
|
| Military Medicine | 2 | 1995 | 54 | 0.060 |
Why?
|
| Vasoconstriction | 1 | 2005 | 120 | 0.060 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 521 | 0.060 |
Why?
|
| Lymphoma | 2 | 2011 | 1514 | 0.060 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2005 | 125 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2017 | 1588 | 0.060 |
Why?
|
| Dyspnea | 2 | 2016 | 421 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2009 | 743 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 7232 | 0.060 |
Why?
|
| Chyle | 1 | 2024 | 22 | 0.060 |
Why?
|
| Syndrome | 4 | 2000 | 1405 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 1055 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 2679 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2009 | 666 | 0.060 |
Why?
|
| Brachytherapy | 2 | 2001 | 1005 | 0.060 |
Why?
|
| Brachial Artery | 2 | 2014 | 44 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 9099 | 0.060 |
Why?
|
| Air Pollutants | 1 | 2005 | 135 | 0.060 |
Why?
|
| Liver | 3 | 2020 | 3123 | 0.060 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 1649 | 0.050 |
Why?
|
| Cisplatin | 3 | 2020 | 2497 | 0.050 |
Why?
|
| Myoblasts | 1 | 2013 | 64 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2019 | 1851 | 0.050 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2014 | 231 | 0.050 |
Why?
|
| Immunotherapy | 3 | 2024 | 3545 | 0.050 |
Why?
|
| Palliative Care | 1 | 1994 | 2159 | 0.050 |
Why?
|
| Mice | 5 | 2016 | 36041 | 0.050 |
Why?
|
| Medicare | 2 | 2019 | 934 | 0.050 |
Why?
|
| Income | 1 | 2023 | 232 | 0.050 |
Why?
|
| International Cooperation | 2 | 2016 | 326 | 0.050 |
Why?
|
| Travel | 1 | 2023 | 200 | 0.050 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2021 | 17 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 1657 | 0.050 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2002 | 42 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 61 | 0.050 |
Why?
|
| Embolism, Air | 1 | 2002 | 35 | 0.050 |
Why?
|
| Diabetes Complications | 2 | 2000 | 316 | 0.050 |
Why?
|
| Prosthesis Failure | 2 | 2000 | 201 | 0.050 |
Why?
|
| Thorax | 2 | 2016 | 231 | 0.050 |
Why?
|
| Telemetry | 2 | 2015 | 41 | 0.050 |
Why?
|
| Creatine Kinase, MB Form | 4 | 2001 | 24 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2004 | 2366 | 0.050 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 554 | 0.050 |
Why?
|
| Cerebral Arteries | 1 | 2002 | 100 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2020 | 2365 | 0.050 |
Why?
|
| Disease Progression | 3 | 2020 | 6909 | 0.050 |
Why?
|
| Fusobacterium necrophorum | 1 | 2000 | 4 | 0.050 |
Why?
|
| Atherectomy | 1 | 2000 | 16 | 0.050 |
Why?
|
| Vascular Patency | 1 | 2001 | 192 | 0.050 |
Why?
|
| Abdomen | 2 | 2016 | 348 | 0.050 |
Why?
|
| Fusobacterium Infections | 1 | 2000 | 30 | 0.050 |
Why?
|
| Thrombophlebitis | 1 | 2000 | 35 | 0.050 |
Why?
|
| Antineoplastic Agents | 4 | 2017 | 14653 | 0.050 |
Why?
|
| Coronary Thrombosis | 1 | 2000 | 42 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2000 | 93 | 0.050 |
Why?
|
| DNA Primers | 1 | 2013 | 1513 | 0.050 |
Why?
|
| Jugular Veins | 1 | 2000 | 113 | 0.040 |
Why?
|
| Neck | 1 | 2022 | 386 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 782 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2006 | 1112 | 0.040 |
Why?
|
| Tissue Array Analysis | 2 | 2014 | 760 | 0.040 |
Why?
|
| Cytokines | 2 | 2020 | 2840 | 0.040 |
Why?
|
| A549 Cells | 1 | 2020 | 128 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 4795 | 0.040 |
Why?
|
| Cause of Death | 3 | 2015 | 787 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2000 | 94 | 0.040 |
Why?
|
| Subphrenic Abscess | 1 | 1999 | 3 | 0.040 |
Why?
|
| Biopsy | 2 | 2020 | 3544 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2000 | 105 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2022 | 492 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2020 | 166 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 493 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 162 | 0.040 |
Why?
|
| Metaplasia | 1 | 2021 | 387 | 0.040 |
Why?
|
| Tracheal Diseases | 1 | 1999 | 36 | 0.040 |
Why?
|
| Peritoneal Diseases | 1 | 1999 | 33 | 0.040 |
Why?
|
| Respiratory Tract Fistula | 1 | 1999 | 34 | 0.040 |
Why?
|
| Sutures | 1 | 2000 | 93 | 0.040 |
Why?
|
| Tunica Intima | 1 | 1999 | 100 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 796 | 0.040 |
Why?
|
| Dogs | 2 | 1991 | 1169 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 321 | 0.040 |
Why?
|
| Vena Cava Filters | 1 | 2000 | 91 | 0.040 |
Why?
|
| Foreign-Body Migration | 1 | 2000 | 122 | 0.040 |
Why?
|
| Portal Vein | 1 | 2021 | 364 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2016 | 566 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2016 | 3646 | 0.040 |
Why?
|
| Fistula | 1 | 1999 | 76 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3928 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 207 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2020 | 377 | 0.040 |
Why?
|
| Troponin I | 1 | 1999 | 131 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 327 | 0.040 |
Why?
|
| Radiology, Interventional | 1 | 2000 | 142 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 787 | 0.040 |
Why?
|
| Colectomy | 1 | 2020 | 291 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2016 | 5804 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2020 | 251 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.040 |
Why?
|
| Creatinine | 2 | 2016 | 546 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 258 | 0.040 |
Why?
|
| Hypotension | 1 | 2000 | 237 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 245 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 474 | 0.040 |
Why?
|
| Fasciitis, Necrotizing | 1 | 1998 | 33 | 0.040 |
Why?
|
| Cell Survival | 2 | 2015 | 3074 | 0.040 |
Why?
|
| Aspirin | 1 | 2001 | 392 | 0.040 |
Why?
|
| Diabetic Angiopathies | 1 | 1998 | 81 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1849 | 0.040 |
Why?
|
| Nomograms | 1 | 2020 | 313 | 0.040 |
Why?
|
| Pemetrexed | 1 | 2017 | 100 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 124 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2013 | 1885 | 0.040 |
Why?
|
| Heart Atria | 1 | 2000 | 357 | 0.040 |
Why?
|
| Prosthesis Implantation | 1 | 1999 | 244 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 636 | 0.040 |
Why?
|
| Streptococcus pyogenes | 1 | 1998 | 130 | 0.040 |
Why?
|
| Thromboplastin | 1 | 1996 | 33 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 910 | 0.040 |
Why?
|
| Medical Laboratory Science | 1 | 1996 | 23 | 0.030 |
Why?
|
| Neoplasms | 1 | 2023 | 15915 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 1996 | 69 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 1996 | 72 | 0.030 |
Why?
|
| Hirudins | 1 | 2016 | 41 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 3512 | 0.030 |
Why?
|
| Iridium Radioisotopes | 3 | 2001 | 57 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 1997 | 257 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2018 | 758 | 0.030 |
Why?
|
| Pressure | 2 | 2012 | 188 | 0.030 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2016 | 15 | 0.030 |
Why?
|
| Kidney | 2 | 2022 | 2265 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 869 | 0.030 |
Why?
|
| Echinococcosis | 1 | 1995 | 14 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 1995 | 13 | 0.030 |
Why?
|
| North America | 1 | 2016 | 341 | 0.030 |
Why?
|
| Biomarkers | 3 | 2022 | 5112 | 0.030 |
Why?
|
| Femoral Artery | 1 | 1996 | 203 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1244 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 89 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 1047 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2015 | 104 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2015 | 233 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 522 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 1827 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 1999 | 408 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2012 | 2864 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1996 | 337 | 0.030 |
Why?
|
| Aneurysm, False | 1 | 1996 | 143 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2015 | 100 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 659 | 0.030 |
Why?
|
| Thrombosis | 1 | 2001 | 755 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2000 | 588 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1241 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2021 | 1891 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 276 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1034 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 691 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 1136 | 0.030 |
Why?
|
| Blood Gas Analysis | 1 | 2014 | 106 | 0.030 |
Why?
|
| Life Tables | 1 | 1994 | 122 | 0.030 |
Why?
|
| Pain | 1 | 2022 | 1696 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2019 | 5840 | 0.030 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 65 | 0.030 |
Why?
|
| Wounds, Gunshot | 1 | 1995 | 150 | 0.030 |
Why?
|
| Epothilones | 1 | 2014 | 55 | 0.030 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1993 | 35 | 0.030 |
Why?
|
| Esophagitis | 1 | 2015 | 210 | 0.030 |
Why?
|
| Pulmonary Emphysema | 1 | 1995 | 157 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 5421 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 405 | 0.030 |
Why?
|
| Contraindications | 1 | 1994 | 155 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2004 | 3176 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2014 | 259 | 0.030 |
Why?
|
| Mucins | 1 | 2015 | 289 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2014 | 183 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 738 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2014 | 114 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2015 | 274 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 960 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 505 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 2011 | 3853 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 1429 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2016 | 222 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 1322 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1243 | 0.030 |
Why?
|
| Exercise Test | 1 | 2014 | 315 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2014 | 2452 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 485 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 321 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2016 | 7300 | 0.030 |
Why?
|
| Military Personnel | 1 | 1995 | 246 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 5186 | 0.030 |
Why?
|
| Leeches | 1 | 1992 | 3 | 0.030 |
Why?
|
| Manometry | 1 | 2012 | 72 | 0.030 |
Why?
|
| Bloodletting | 1 | 1992 | 6 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 237 | 0.030 |
Why?
|
| Aorta, Thoracic | 1 | 1996 | 532 | 0.030 |
Why?
|
| Electrocardiography | 3 | 2005 | 1196 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 5104 | 0.030 |
Why?
|
| Gastrointestinal Motility | 1 | 2012 | 88 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 247 | 0.020 |
Why?
|
| General Surgery | 1 | 1995 | 331 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 2575 | 0.020 |
Why?
|
| Skin | 2 | 2014 | 1284 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2016 | 684 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2017 | 2619 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 435 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 326 | 0.020 |
Why?
|
| Pleural Effusion, Malignant | 1 | 1993 | 160 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 215 | 0.020 |
Why?
|
| Obesity | 2 | 2016 | 2958 | 0.020 |
Why?
|
| Temperature | 1 | 2013 | 540 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 1993 | 219 | 0.020 |
Why?
|
| Consensus | 1 | 2016 | 1116 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 1992 | 151 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1074 | 0.020 |
Why?
|
| Hematemesis | 1 | 2011 | 9 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 2 | 2001 | 616 | 0.020 |
Why?
|
| Vasodilation | 1 | 2012 | 218 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 685 | 0.020 |
Why?
|
| Apoptosis | 2 | 2016 | 7837 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1606 | 0.020 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2010 | 38 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2012 | 249 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2014 | 494 | 0.020 |
Why?
|
| Muscles | 1 | 1992 | 461 | 0.020 |
Why?
|
| Sirolimus | 1 | 2015 | 833 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 917 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 3072 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 1248 | 0.020 |
Why?
|
| Catheterization | 1 | 2013 | 425 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 253 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1998 | 850 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1991 | 245 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 5996 | 0.020 |
Why?
|
| Algorithms | 2 | 2014 | 3923 | 0.020 |
Why?
|
| Radiography | 3 | 2000 | 1993 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2015 | 743 | 0.020 |
Why?
|
| Macrophages | 1 | 1996 | 1377 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1212 | 0.020 |
Why?
|
| Fatigue | 1 | 2016 | 1280 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2014 | 973 | 0.020 |
Why?
|
| Hematoma | 1 | 2011 | 159 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 2106 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2011 | 150 | 0.020 |
Why?
|
| Benzamides | 1 | 2015 | 1882 | 0.020 |
Why?
|
| Phagocytosis | 1 | 1991 | 296 | 0.020 |
Why?
|
| Scleroderma, Systemic | 1 | 2011 | 164 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2400 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2010 | 656 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2010 | 323 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 2034 | 0.020 |
Why?
|
| Probability | 2 | 2001 | 887 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 5432 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3363 | 0.020 |
Why?
|
| Spleen | 1 | 1991 | 732 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2009 | 477 | 0.020 |
Why?
|
| Respiratory Mucosa | 1 | 2009 | 211 | 0.020 |
Why?
|
| Graft Survival | 1 | 1992 | 1092 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 499 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6210 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2009 | 201 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 354 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1998 | 1435 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 2496 | 0.020 |
Why?
|
| Stroke | 1 | 2016 | 1094 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 3651 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1842 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 4495 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 686 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8602 | 0.020 |
Why?
|
| Surgical Stapling | 1 | 2007 | 35 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 1482 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 718 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 316 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2006 | 97 | 0.020 |
Why?
|
| Esophageal Stenosis | 1 | 2007 | 91 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2006 | 26 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2015 | 1544 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2014 | 2435 | 0.020 |
Why?
|
| Piperazines | 1 | 2015 | 2152 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 4639 | 0.020 |
Why?
|
| Volatilization | 1 | 2005 | 8 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 674 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 2624 | 0.020 |
Why?
|
| Bosnia and Herzegovina | 2 | 1995 | 4 | 0.020 |
Why?
|
| Pelvis | 1 | 2007 | 384 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 872 | 0.020 |
Why?
|
| Bradycardia | 1 | 2005 | 74 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3689 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 2129 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 1948 | 0.020 |
Why?
|
| Heart Conduction System | 1 | 2005 | 161 | 0.010 |
Why?
|
| Canada | 2 | 1995 | 441 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 1402 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2006 | 835 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 917 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2009 | 1740 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 3022 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 1423 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2006 | 706 | 0.010 |
Why?
|
| Fibrosis | 1 | 2006 | 746 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2009 | 1568 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2007 | 488 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 13931 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 1742 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 3472 | 0.010 |
Why?
|
| Barotrauma | 1 | 2002 | 5 | 0.010 |
Why?
|
| Heart Rate | 1 | 2005 | 761 | 0.010 |
Why?
|
| Models, Biological | 1 | 1991 | 3223 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2006 | 1732 | 0.010 |
Why?
|
| Beta Particles | 1 | 2001 | 9 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 16999 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 1436 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2001 | 139 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2007 | 1349 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2001 | 241 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2009 | 1734 | 0.010 |
Why?
|
| Time | 1 | 2001 | 186 | 0.010 |
Why?
|
| Gamma Rays | 1 | 2001 | 241 | 0.010 |
Why?
|
| District of Columbia | 1 | 2000 | 19 | 0.010 |
Why?
|
| Brachiocephalic Veins | 1 | 2000 | 20 | 0.010 |
Why?
|
| Cineangiography | 1 | 1999 | 17 | 0.010 |
Why?
|
| Pulmonary Edema | 1 | 2000 | 81 | 0.010 |
Why?
|
| Surface Properties | 1 | 2000 | 188 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2001 | 322 | 0.010 |
Why?
|
| Vena Cava, Superior | 1 | 2000 | 78 | 0.010 |
Why?
|
| Health Resources | 1 | 2001 | 173 | 0.010 |
Why?
|
| Carcinoma | 1 | 2011 | 2623 | 0.010 |
Why?
|
| Retreatment | 1 | 2000 | 447 | 0.010 |
Why?
|
| Pneumonia | 1 | 2005 | 798 | 0.010 |
Why?
|
| Carotid Stenosis | 1 | 2000 | 160 | 0.010 |
Why?
|
| Catheterization, Peripheral | 1 | 2000 | 159 | 0.010 |
Why?
|
| Retroperitoneal Space | 1 | 1998 | 156 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 4195 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 4993 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2002 | 522 | 0.010 |
Why?
|
| Microcirculation | 1 | 1997 | 195 | 0.010 |
Why?
|
| Catheterization, Central Venous | 1 | 2000 | 366 | 0.010 |
Why?
|
| Appendicitis | 1 | 1998 | 175 | 0.010 |
Why?
|
| Echinococcosis, Pulmonary | 1 | 1995 | 1 | 0.010 |
Why?
|
| Echinococcosis, Hepatic | 1 | 1995 | 8 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1996 | 323 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 6515 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 2711 | 0.010 |
Why?
|
| Inpatients | 1 | 1999 | 695 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1999 | 1988 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2001 | 931 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1998 | 531 | 0.010 |
Why?
|
| Equipment Design | 1 | 1996 | 1207 | 0.010 |
Why?
|
| Lipids | 1 | 1996 | 662 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 483 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2000 | 1076 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2000 | 4399 | 0.010 |
Why?
|
| Ischemia | 1 | 1992 | 407 | 0.010 |
Why?
|
| Rats | 1 | 1992 | 6638 | 0.000 |
Why?
|